Nexalin Technology (NXL) Cash & Current Investments (2021 - 2026)
Nexalin Technology (NXL) recorded quarterly Cash & Current Investments of $2.7 million in Q1 2026, down 55.87% quarter-over-quarter from $6.1 million in Q4 2025, and up 32.05% on a YoY basis from $2.1 million in Q1 2025.
Nexalin Technology (NXL) Cash & Current Investments (2021 - 2026) Analysis & Trends
Nexalin Technology's Cash & Current Investments history runs 6 years deep, the most recent figure standing at $2.7 million for Q1 2026.
- In Q1 2026, Cash & Current Investments rose 32.05% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $2.7 million (up 32.05% YoY), while the FY2025 annual figure was $6.1 million, up 76.35% from the prior year.
- Cash & Current Investments was $2.7 million for Q1 2026 at Nexalin Technology, down from $6.1 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $13.7 million in Q4 2022 to a low of $848796.0 in Q2 2024.
- Historically, Cash & Current Investments has averaged $5.7 million across 5 years, with a median of $4.7 million in 2023.
- The sharpest annual moves came in 2022 and 2024: Cash & Current Investments surged 1964.5% in 2022, then tumbled 90.49% in 2024.
- A 5-year view of Cash & Current Investments shows it stood at $13.7 million in 2022, then tumbled by 65.33% to $4.7 million in 2023, then decreased by 26.53% to $3.5 million in 2024, then soared by 76.35% to $6.1 million in 2025, then slumped by 55.87% to $2.7 million in 2026.
- The last three Cash & Current Investments figures came in at $2.7 million (Q1 2026), $6.1 million (Q4 2025), and $7.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 7.30 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 2.88 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 8.38 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 1.45 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 3.67 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 3.12 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 1.12 Bn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 2.29 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 439.60 Mn |
| 10 | Nexalin Technology | 7.82 Mn | 5.11 Mn | 13,133.00 | 2.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.71 Mn |
| Dec 31, 2025 | 6.14 Mn |
| Sep 30, 2025 | 7.53 Mn |
| Jun 30, 2025 | 10.72 Mn |
| Mar 31, 2025 | 2.05 Mn |
| Dec 31, 2024 | 3.48 Mn |
| Sep 30, 2024 | 4.59 Mn |
| Jun 30, 2024 | 848,796.00 |
| Mar 31, 2024 | 3.20 Mn |
| Dec 31, 2023 | 4.74 Mn |
| Sep 30, 2023 | 3.94 Mn |
| Jun 30, 2023 | 8.93 Mn |
| Mar 31, 2023 | 5.47 Mn |
| Dec 31, 2022 | 13.66 Mn |
| Sep 30, 2022 | 7.86 Mn |
| Dec 31, 2021 | 661,778.00 |